Survodutide: 6mg
Weight managementDescription
Survodutide is a dual agonist of the glp-1 and glucagon receptors — a distinct mechanism from the glp-1/gip dual agonist class. where gip receptor activation enhances insulin sensitivity and fat storage regulation, glucagon receptor activation increases hepatic glucose output and energy expenditure. this pairing makes survodutide particularly relevant in research focused on metabolic liver disease, including non-alcoholic fatty liver disease (nafld) and metabolic dysfunction-associated steatohepatitis (mash), in addition to weight loss. its phase 3 trial results are pending as of 2025. the glucagon component is associated with increased resting energy expenditure, which may explain the chronic fatigue benefits observed in preliminary research. for research and educational purposes only.
Specifications
| Amount in Vial | 6mg |
|---|---|
| BAC Water | 1ml |
| Amount per Unit | 0.06mg per unit |
| Recommended Dose | titrate up from 600mcg to 4.5mg (10 to 75 units) |
| Frequency | 1x per week |
| Injection Type | Subcutaneous |
| Timing | Same Day Every Week / Starting Dose Is 600MCG |
Dose Calculator
Based on 0.06mg per unit (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 6mg
Add BAC water: 1ml
Concentration: 0.06mg per unit
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.